Bloom Burton Comments on Repare Therapeutics Inc.’s FY2024 Earnings (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) – Analysts at Bloom Burton increased their FY2024 EPS estimates for shares of Repare Therapeutics in a research note issued on Thursday, September 12th. Bloom Burton analyst D. Martin now expects that the company will earn ($1.94) per share for the year, up from their prior estimate of ($2.92). The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.31) per share.

RPTX has been the topic of several other research reports. Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Wednesday, September 4th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $17.33.

Repare Therapeutics Stock Up 17.7 %

Shares of NASDAQ RPTX opened at $3.53 on Monday. Repare Therapeutics has a 1-year low of $2.71 and a 1-year high of $13.85. The company has a 50-day moving average of $3.26 and a two-hundred day moving average of $3.74.

Repare Therapeutics (NASDAQ:RPTX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.03. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RPTX. Blue Owl Capital Holdings LP increased its stake in shares of Repare Therapeutics by 8.0% in the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after buying an additional 250,000 shares during the period. Squarepoint Ops LLC increased its holdings in shares of Repare Therapeutics by 428.4% during the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock valued at $472,000 after acquiring an additional 115,916 shares in the last quarter. Marshall Wace LLP acquired a new position in Repare Therapeutics during the 2nd quarter valued at about $273,000. Bank of Montreal Can grew its stake in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after acquiring an additional 5,673 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Repare Therapeutics in the second quarter valued at about $110,000. 85.09% of the stock is currently owned by institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.